A polymorphism of the plasminogen activator inhibitor-1 gene promoter and the polycystic ovary syndrome.
OBJECTIVE
To investigate the association of a common 5G/4G polymorphism of the plasminogen activator inhibitor-1 gene (PAI1) with occurrence and clinical characteristics of the polycystic ovary syndrome (PCOS).


METHODS
In a case-control study, we evaluated a series of 106 Caucasian women with PCOS and 102 healthy controls. Women completed a detailed questionnaire and underwent a peripheral venous puncture, ultrasonography, and a standardized oral glucose tolerance test (OGTT). The PAI1 gene promoter polymorphism was evaluated using PCR.


RESULTS
Allele and genotype frequencies were not significantly different among women with PCOS and controls (P=0.3 and 0.6, respectively). In women with PCOS, presence of the 5G/4G polymorphism of PAI1 was not associated with changes in serum hormone levels or with clinical characteristics.


CONCLUSIONS
The 5G/4G polymorphism of the PAI1 promoter is not associated with occurrence and phenotype of the PCOS.
Walch
Katharina
K
Department of Obstetrics and Gynecology, Division of Gynecological Endocrinology and Infertility Treatment, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria. katharina.walch@meduniwien.ac.at
Grimm
Christoph
C
Huber
Johannes C
JC
Nagele
Friedrich
F
Kolbus
Andrea
A
Hefler
Lukas A
LA
D000328:Adult; D016022:Case-Control Studies; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D011085:Polycystic Ovary Syndrome / Q000209:etiology / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic / Q000235:genetics; D044465:White People / Q000235:genetics
D017395:Plasminogen Activator Inhibitor 1